Primary source: What is an Early Alert?
Translated From Korean
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
The issue has been classified as a Class II Recall. The FDA added additional lot numbers to the affected product list and notified the public of potential health risks associated with the use of non-sterile kits.
This corrective action addresses health risks associated with non-sterile components in medical devices, ensuring patient safety and compliance with regulatory standards.
Affected healthcare facilities and distributors must immediately check their stock, remove BD ChloraPrep applicators from all kits, apply over-labels indicating the need for component removal, and notify any customers if they have transferred or resold these products.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Affected healthcare facilities and distributors must immediately check their stock, remove BD ChloraPrep applicators from all kits, apply over-labels indicating the need for component removal, and notify any customers if they have transferred or resold these products.
The FDA updated communication on a Class II Recall for Medline Convenience Kits containing BD ChloraPrep Applicators due to concerns that some kits may not be sterile. This includes specific guidance to remove affected components and apply over-labels to inform users of required actions.
What changed: The issue has been classified as a Class II Recall. The FDA added additional lot numbers to the affected product list and notified the public of potential health risks associated with the use of non-sterile kits.
Why it matters: This corrective action addresses health risks associated with non-sterile components in medical devices, ensuring patient safety and compliance with regulatory standards.
Practical implication: Affected healthcare facilities and distributors must immediately check their stock, remove BD ChloraPrep applicators from all kits, apply over-labels indicating the need for component removal, and notify any customers if they have transferred or resold these products.
Published from the regulator source ingestion pipeline after PV impact triage.
Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.
Companies must ensure compliance with the Irish language requirements and complete mandatory OMS registration before regulatory submissions to prevent delays.
Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.
Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.
